Brief: Ligand Collaborator Merck Receives FDA Approval For Pneumococcal Vaccine For Adults
18/06/2024 13:17
June 18 (Reuters) - Ligand Pharmaceuticals Inc LGND.O :
* LIGAND COLLABORATOR MERCK RECEIVES FDA APPROVAL FOR
CAPVAXIVE™
(PNEUMOCOCCAL 21-VALENT CONJUGATE VACCINE) FOR ADULTS
* LIGAND PHARMACEUTICALS INC: LIGAND IS ENTITLED TO A
ROYALTY ON
WORLDWIDE NET SALES OF CAPVAXIVE
Source text for Eikon: ID:nBw4VHYWFa
Further company coverage: LGND.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ligand Pharmaceuticals Incorporated
See all newsBrief: Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million
Ligand Pharmaceuticals Incorporated reports results for the quarter ended June 30 - Earnings Summary
Ligand Pharmaceuticals Q2 revenue rises on royalty growth
Brief: Ligand Pharmaceuticals Q2 EPS USD 2.22
U.S. RESEARCH ROUNDUP-Equinix, Goldman Sachs, JPMorgan